Annals of Surgical Oncology

, Volume 16, Issue 9, pp 2609–2616 | Cite as

High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma

  • Jen-Der Lin
  • Tzu-Chieh Chao
  • Chuen Hsueh
  • Sheng-Fong Kuo
Endocrine Tumors

Abstract

Background

Multicentric papillary thyroid carcinoma (PTC) is not unusual in patients with PTC. However, its clinical features concerning cancer recurrence and mortality are not well described.

Methods

A total of 1682 PTC patients at a single institution who underwent total thyroidectomy were retrospectively reviewed; the mean follow-up period was 7.7 ± 0.1 years. Postoperative radioactive iodide ablation for thyroid remnant was performed after surgery for most patients.

Results

Of all the PTC cases reviewed, 337 cases (20.0%) were categorized as multicentric PTC. Compared with patients with unifocal PTC, multicentric PTC patients demonstrated older age, advanced TNM staging, and higher recurrence. A higher recurrence rate for multicentric PTC (20.2%) was observed compared with that for unifocal PTC; 45.8% of multicentric PTC cases with ≥ 5 foci experienced cancer recurrence. Mean tumor size of the largest nodule in patients with multicentric PTC was significantly smaller than that found in unifocal PTC. Patients with multicentric papillary microcarcinoma (≤1 cm) had higher recurrence rate and cancer mortality than those with unifocal papillary microcarcinoma. Of the recurrent multicentric PTC cases, 52.9% were persistent or diagnosed within the first year of thyroidectomy and had a cancer-related mortality of 27.8%. The 5-, 10-, and 20-year survival rates of multicentric PTC patients were 97.7%, 94.4%, and 84.7%, respectively, which were not statistically different from those of unifocal PTC patients.

Conclusions

Multicentric PTC warrant postoperative adjuvant therapy and close surveillance within the first year. Patients with multicentric papillary thyroid microcarcinoma need to be treated as high-risk patients.

References

  1. 1.
    Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol. 2006;13:1524–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Low TH, Delbridge L, Sidhu S, Learoyd D, Robinson B, Roach P, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al. The heterogenous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3511–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Sobin LH, UICC (2002) Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52–6.Google Scholar
  6. 6.
    Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Delellis RA, Lloyd RV, Heitx PU, Eng C. Pathology and genetics of tumors of endocrine organs. In: World health organization of tumours. Lyon: IARC; 2004. p. 73–6.Google Scholar
  8. 8.
    Zhang DD, Zhou XH, Freeman DH, Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Simonowitz D, Thomsen S, Moossa AR, Block GE. The treatment of incidental papillary thyroid cancer. Arch Surg. 1976;111:477–83.PubMedGoogle Scholar
  10. 10.
    Miyaki M, Iijima T, Ishii R, Hishima T, Mori T, Yoshinaga K, et al. Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis. Am J Pathol. 2000;157:1825–7.PubMedGoogle Scholar
  11. 11.
    Gerfo PL, Chabot J, Gazetas P. The intraoperative incidence of detectable bilateral and multicentric disease in papillary cancer of the thyroid. Surgery. 1990;108:958–62.PubMedGoogle Scholar
  12. 12.
    Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg. 2008;32:678–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Stoffer SS, Van Dyke DL, Bach JV, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986;25:775–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, et al. Geographic mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer. 2008;7:89.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutation status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol. 2009;16:240–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, et al. BRAF (V600E) mutation and p27 (kip1) expression in papillary carcinomas of the thyroid </=1 cm and their paired lymph node metastases. Cancer. 2007;110:1218–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol. 2005;63:588–93.CrossRefGoogle Scholar
  20. 20.
    Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319–25.PubMedCrossRefGoogle Scholar
  23. 23.
    Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo A, Foletto M, et al. Complications in thyroid surgery for carcinoma: one institution’s surgical experience. World J Surg. 2008;32:572–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, Broelsch CE. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 2000;128:1067–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11.PubMedCrossRefGoogle Scholar
  27. 27.
    Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med. 2005;43:843–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, et al. Outcome predictors and impact of central node dissection and radiometabolic treatment in papillary thyroid cancers <=2 cm. Endocr Relat Cancer. 2009;16:201–10.PubMedCrossRefGoogle Scholar
  30. 30.
    Noguchi S, Yamashita H, Uchino S. Modified radical neck dissection is better than partial dissection of lymph nodes. World J Surg. 2009;33:394–6.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Jen-Der Lin
    • 1
  • Tzu-Chieh Chao
    • 2
  • Chuen Hsueh
    • 3
  • Sheng-Fong Kuo
    • 1
  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C
  2. 2.Department of General SurgeryChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C
  3. 3.Department of PathologyChang Gung Memorial Hospital, Chang Gung UniversityKweishan County, Taoyuan HsienTaiwan R.O.C

Personalised recommendations